BCLSI
OLMA icon

Bain Capital Life Sciences Investors’s Olema Pharmaceuticals OLMA Stock Holding History

Bain Capital Life Sciences Investors’s Portfolio OLMA Stock Details OLMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$111M Sell
7,473,238
-1,035,403
-12% -$23M 10.05% 3
2025
Q4 		$213M Buy
8,508,641
+1,664,687
+24% +$29.6M 16.29% 3
2025
Q3 		$67M Hold
6,843,954
– – 4.45% 5
2025
Q2 		$29.2M Hold
6,843,954
– – 3.65% 9
2025
Q1 		$25.7M Sell
6,843,954
-626,260
-8% -$3.15M 3.81% 8
2024
Q4 		$43.6M Buy
+7,470,214
New +$74.6M 5.12% 7

Other funds holding OLMA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Bain Capital Life Sciences Investors's OLMA Position: Q1 2026 in Review

Bain Capital Life Sciences Investors reduced its Olema Pharmaceuticals (OLMA) stake by 12% in Q1 2026, selling an estimated $23M and leaving 7,473,238 shares worth $111M. The position accounts for 10.05% of the portfolio, ranked #3.

Bain Capital Life Sciences Investors first reported a position in OLMA in Q4 2024 and has held it in 6 quarters since. The position peaked at $213M in Q4 2025. 195 funds tracked by Wall St. Rank hold OLMA as of Q1 2026.

  • Bain Capital Life Sciences Investors held 7,473,238 shares of Olema Pharmaceuticals worth $111M as of Q1 2026.
  • Bain Capital Life Sciences Investors sold 1,035,403 Olema Pharmaceuticals shares in Q1 2026, an estimated $23M.
  • Olema Pharmaceuticals made up 10.05% of Bain Capital Life Sciences Investors's portfolio in Q1 2026, its #3 holding.
  • Bain Capital Life Sciences Investors first reported a position in Olema Pharmaceuticals in Q4 2024 and has held it in 6 quarters since.
  • Bain Capital Life Sciences Investors's Olema Pharmaceuticals position peaked at $213M in Q4 2025.
  • 195 funds tracked by Wall St. Rank held Olema Pharmaceuticals as of Q1 2026.

Based on Bain Capital Life Sciences Investors's 13F filing for Q1 2026, filed 15 May 2026.